Cost-minimization analysis of treprostinil vs. epoprostenol as an alternate to oral therapy non-responders for the treatment of pulmonary arterial hypertension

References

• Pass S, Dusing M. Current and emerging therapy for pulmonary hypertension. Ann Pharmacother 2002;36:1414–23
   PubMed Web of Science ®Google Scholar
• British Cardiac Society Guidelines and Medical Practice Committee. Recommendations on the management of pulmonary hypertension in clinical practice. Heart 2001;86:i1–i13
   PubMed Web of Science ®Google Scholar
• Gaine S, Rubin L. Primary pulmonary hypertension. Lancet 1998;352:719–25
   PubMed Web of Science ®Google Scholar
• D’Alonzo G, Barst R, Ayres S, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343–9
   Google Scholar
• Rich S. Primary pulmonary hypertension. Curr Treat Options Cardiovasc Med 2000;2:135–40
   PubMedGoogle Scholar
• Rich S. Medical treatment of primary pulmonary hypertension: a bridge to transplantation? Am J Cardiol 1995;75:63A–6A
   Google Scholar
• Gildea T, Arroliga A, Minai A. Treatments and strategies to optimize the comprehensive management of patients with pulmonary arterial hypertension. Clevel Clin J Med 2003;70: S18–S27
   Google Scholar
• Channick R, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119–23
   PubMed Web of Science ®Google Scholar
• Chen SJ, Chen YF, Meng QC, Durand J, Dicarlo VS, Oparil S. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 1995;79:2122–31
   PubMed Web of Science ®Google Scholar
• Rubin L, Badesch D, Barst R, et al. Bosentan therapy for pulmonary arterial hypertension. New Engl J Med 2002;346:896–903
   PubMed Web of Science ®Google Scholar
• FDA. Flolan approval letter. 2000. http://www.fda.gov/cder/foi/nda/2000/20–444S003_Flolan_Approv.pdf [accessed June 15, 2005]
   Google Scholar
• McLaughlin V, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477–82
   PubMed Web of Science ®Google Scholar
• Simonneau G, Barst R, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800–4
   PubMed Web of Science ®Google Scholar
• McLaughlin VV. Improvement in exercise tolerance with treprostinil is dose related for pulmonary arterial hypertension. American Thoracic Society (ATS) 2002 International Conference; 1–2, 2002
   Google Scholar
• FDA. Remodulin approval letter. 2002. http://www.fda.gov/cder/foi/nda/2002/21–272_Remodulin_Approv.pdf [accessed June 2005]
   Google Scholar
• United Therapeutics Corporation. Product monograph: Remodulin [treprostinil sodium] injection. 2004
   Google Scholar
• Highland K, Strange C, Mazur J, Simpson K. Treatment of pulmonary arterial hypertension: a preliminary decision analysis. Chest 2003;124:2087–92
   PubMed Web of Science ®Google Scholar
• Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada, 2nd ed. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1997
   Google Scholar
• Jacobs P, Bachynsky J, Baladi J. A comparative review of pharmacoeconomic guidelines. Pharmacoeconomics 1995; 8:182–9
   PubMedGoogle Scholar
• Torrance G, Blaker D, Detsky A, et al. Canadian guidelines for economic evaluation of pharmaceuticals: Canadian collaboration workshop for pharmacoeconomics. Pharmacoeconomics 1996;9:535–59
   PubMedGoogle Scholar
• Gibbs JS. Chronic infusion of treprostinil is safe, and appears to prolong survival over a three-year period in patients with pulmonary arterial hypertension. American Heart Association (AHA) Scientific Sessions 2002; 1–3, 2002
   Google Scholar
• Shapiro S, Oudiz R, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am College Cardiol 1997;30:343–9
   PubMed Web of Science ®Google Scholar
• Barst R, Rubin L, McGoon M, Caldwell E, Long W, Levy P. Survival of primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409–15
   PubMed Web of Science ®Google Scholar
• Vachiery J, Hill N, Zwicke D, Barst R, Blackburn S, Naeije R. Transitioning from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest 2002;121:1561–5
   PubMed Web of Science ®Google Scholar
• Rich S, Dantzker R, Ayres S, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:249–23
   Google Scholar
• Galie N, Manes A, Branzi A. Medical therapy of pulmonary hypertension. The prostacyclins. Clin Chest Med 2001;22:529–37
   PubMed Web of Science ®Google Scholar
• Widlitz A, Barst R. Pulmonary arterial hypertension in children. Eur Respir J 2003;21:155–76
   PubMed Web of Science ®Google Scholar
• Schulman K, Glick H, Buxton M, et al. The economic evaluation of the FIRST study: design of a prospective analysis alongside a multinational phase III clinical trial. Control Clin Trials 1996;17:304–15
   PubMedGoogle Scholar
• Banayan D, Witt J, McCarthy M, Granton JT. The direct and indirect costs of chronic intravenous epoprostenol in patients with pulmonary arterial hypertension. ATS 99th International Conference,16-5–2003
   Google Scholar
• Angus D, Linde-Zwirble W, Lidicker J, Clermont G, Carcillo J, Pinksy M. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303–10
   PubMed Web of Science ®Google Scholar
• Schulman K, Buxton M, Glick H. Results of the economic evaluation of the FIRST study. Int J Tech Assess Health Care 1996;12:698–713
   Google Scholar
• Teres D, Rapoport J, Lemeshow S, Kim S, Akhras K. Effects of severity of illness on resource use by survivors and nonsurvivors of severe sepsis at intensive care unit admission. Crit Care Med 2002;30:2413–9
   Google Scholar
• Anon. Treprostinil (Remodulin) for pulmonary arterial hyper-tension. Med Lett 2002;44:80–2
   Google Scholar